Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-12

AUTHORS

Harvey I. Pass, Barbara K. Temeck, Karen Kranda, Gunther Thomas, Angelo Russo, Paul Smith, Walt Friauf, Seth M. Steinberg

ABSTRACT

Background: Patients with malignant pleural mesothelioma (MPM) usually die of progressive local disease. This report describes the results of a Phase III trial comparing maximum debulking surgery and postoperative cisplatin, interferon α-2b, and tamoxifen (CIT) immunochemotherapy with and without intraoperative photodynamic therapy (PDT) to determine (1) whether such a multimodal approach can be performed with minimum morbidity and mortality in malignant pleural mesothelioma (MPM), and (2) whether first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT impacts on local recurrence or survival.Methods: From July 1993 to June 1996, 63 patients with localized MPM were randomized to either PDT or no PDT. The tumors of 15 patients could not be debulked to 5 mm. Patients assigned to PDT (n=25) and no PDT (n=23) were similar with respect to age, sex, tumor volume, and histology.Results: The type of resection (11 pleurectomies and 14 pneumonectomies vs. 12 pleurectomies and 11 pneumonectomies), length postoperative stay, and ICU time were comparable (PDT vs. no PDT). There was one operative death (hemorrhage), and each group had two bronchopleural fistulas. Postoperative staging divided patients into the following categories: stage I: PDT, 2, no PDT, 2; stage II: PDT, 2, no PDT, 2; stage III, PDT, 21; no PDT, 17; stage IV, PDT, 0; 0; no PDT, 2. Comparable numbers of CIT cycles were delivered. Median survival for the 15 non-debulked patients was 7.2 months, compared to 14 months for the 48 patients on protocol. There were no differences in median survival (14.4 vs. 14.1 months) or median progression-free time (8.5 vs. 7.7 months), and sites of first recurrence were similar.Conclusions: Aggressive multimodal therapy can be delivered for patients with higher stage MPM. First-generation PDT does not prolong survival or increase local control for MPM. More... »

PAGES

628-633

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02303746

DOI

http://dx.doi.org/10.1007/bf02303746

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051247127

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9416409


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon alpha-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intraoperative Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mesothelioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Photochemotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pleural Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pass", 
        "givenName": "Harvey I.", 
        "id": "sg:person.0763326335.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763326335.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Temeck", 
        "givenName": "Barbara K.", 
        "id": "sg:person.01306041342.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306041342.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kranda", 
        "givenName": "Karen", 
        "id": "sg:person.01032321717.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032321717.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas", 
        "givenName": "Gunther", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Russo", 
        "givenName": "Angelo", 
        "id": "sg:person.01046205245.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046205245.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "Paul", 
        "id": "sg:person.014154611317.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014154611317.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Friauf", 
        "givenName": "Walt", 
        "id": "sg:person.015660165207.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015660165207.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steinberg", 
        "givenName": "Seth M.", 
        "id": "sg:person.014210640617.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014210640617.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf02303538", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003120273", 
          "https://doi.org/10.1007/bf02303538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1991.474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014661732", 
          "https://doi.org/10.1038/bjc.1991.474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02307026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018395434", 
          "https://doi.org/10.1007/bf02307026"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1997-12", 
    "datePublishedReg": "1997-12-01", 
    "description": "Background: Patients with malignant pleural mesothelioma (MPM) usually die of progressive local disease. This report describes the results of a Phase III trial comparing maximum debulking surgery and postoperative cisplatin, interferon \u03b1-2b, and tamoxifen (CIT) immunochemotherapy with and without intraoperative photodynamic therapy (PDT) to determine (1) whether such a multimodal approach can be performed with minimum morbidity and mortality in malignant pleural mesothelioma (MPM), and (2) whether first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT impacts on local recurrence or survival.Methods: From July 1993 to June 1996, 63 patients with localized MPM were randomized to either PDT or no PDT. The tumors of 15 patients could not be debulked to 5 mm. Patients assigned to PDT (n=25) and no PDT (n=23) were similar with respect to age, sex, tumor volume, and histology.Results: The type of resection (11 pleurectomies and 14 pneumonectomies vs. 12 pleurectomies and 11 pneumonectomies), length postoperative stay, and ICU time were comparable (PDT vs. no PDT). There was one operative death (hemorrhage), and each group had two bronchopleural fistulas. Postoperative staging divided patients into the following categories: stage I: PDT, 2, no PDT, 2; stage II: PDT, 2, no PDT, 2; stage III, PDT, 21; no PDT, 17; stage IV, PDT, 0; 0; no PDT, 2. Comparable numbers of CIT cycles were delivered. Median survival for the 15 non-debulked patients was 7.2 months, compared to 14 months for the 48 patients on protocol. There were no differences in median survival (14.4 vs. 14.1 months) or median progression-free time (8.5 vs. 7.7 months), and sites of first recurrence were similar.Conclusions: Aggressive multimodal therapy can be delivered for patients with higher stage MPM. First-generation PDT does not prolong survival or increase local control for MPM.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf02303746", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "keywords": [
      "malignant pleural mesothelioma", 
      "intraoperative photodynamic therapy", 
      "pleural mesothelioma", 
      "median survival", 
      "median progression-free time", 
      "progression-free time", 
      "progressive local disease", 
      "aggressive multimodal therapy", 
      "photodynamic therapy", 
      "phase III trials", 
      "type of resection", 
      "trial of surgery", 
      "intrapleural photodynamic therapy", 
      "postoperative cisplatin", 
      "ICU time", 
      "operative deaths", 
      "postoperative immunochemotherapy", 
      "postoperative stay", 
      "minimum morbidity", 
      "first recurrence", 
      "local recurrence", 
      "local disease", 
      "bronchopleural fistula", 
      "multimodal therapy", 
      "tumor volume", 
      "stage III", 
      "patients", 
      "stage I", 
      "stage IV", 
      "local control", 
      "interferon \u03b1-2b", 
      "stage II", 
      "mesothelioma", 
      "therapy", 
      "phase III", 
      "immunochemotherapy", 
      "survival", 
      "multimodal approach", 
      "surgery", 
      "recurrence", 
      "trials", 
      "months", 
      "comparable number", 
      "morbidity", 
      "resection", 
      "fistula", 
      "stay", 
      "tumors", 
      "\u03b1-2b", 
      "histology", 
      "mortality", 
      "disease", 
      "cisplatin", 
      "death", 
      "age", 
      "sex", 
      "report", 
      "group", 
      "control", 
      "differences", 
      "time", 
      "protocol", 
      "volume", 
      "categories", 
      "sites", 
      "number", 
      "types", 
      "results", 
      "cycle", 
      "respect", 
      "approach", 
      "III trial", 
      "tamoxifen (CIT) immunochemotherapy", 
      "first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT", 
      "length postoperative stay", 
      "CIT cycles", 
      "non-debulked patients", 
      "higher stage MPM", 
      "stage MPM", 
      "First-generation PDT"
    ], 
    "name": "Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma", 
    "pagination": "628-633", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051247127"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02303746"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9416409"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02303746", 
      "https://app.dimensions.ai/details/publication/pub.1051247127"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_297.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf02303746"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02303746'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02303746'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02303746'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02303746'


 

This table displays all metadata directly associated to this object as RDF triples.

285 TRIPLES      22 PREDICATES      129 URIs      118 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02303746 schema:about N26116fda0d9b4509965b27291a0ccbe9
2 N2696d5ce22b0492db26009df008e8e21
3 N2f0470cc0bea4039b3a5efd7218b6b11
4 N40672a08826742b2a35657ccbb647f37
5 N484c3567b13741949daac0a390baeeb9
6 N543bef448f2242119a96e2827ddb597a
7 N73408d7625604366a62eb357d4adb7a2
8 N878101eae1f04370a32a2a61003a0888
9 Na77a5e48358f4139a690392bedf04995
10 Nb0ad0a07ac2e4d43b6ad4e8850da10c2
11 Nb304d83e58884f60a548b108cc2af0f8
12 Nb96a1976289c4d1599bf495193190628
13 Nc4592f11f33b4ffab3b6386b72518a64
14 Ncebbee43f1554ae7bbbc44e57d0a6951
15 Ncf2c57ca990b493f95c76ace98bfbf95
16 Nd1dac1e8a4494e62a964895f684aab63
17 Nd60d8f64436f461a8688ec58a264e1c7
18 Ne0bd834aff2a436db683f70664bfa866
19 Nfd2133ce507d4a30bf92717dbde9b467
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N181229cce84047c790eb242acf9b5173
23 schema:citation sg:pub.10.1007/bf02303538
24 sg:pub.10.1007/bf02307026
25 sg:pub.10.1038/bjc.1991.474
26 schema:datePublished 1997-12
27 schema:datePublishedReg 1997-12-01
28 schema:description Background: Patients with malignant pleural mesothelioma (MPM) usually die of progressive local disease. This report describes the results of a Phase III trial comparing maximum debulking surgery and postoperative cisplatin, interferon α-2b, and tamoxifen (CIT) immunochemotherapy with and without intraoperative photodynamic therapy (PDT) to determine (1) whether such a multimodal approach can be performed with minimum morbidity and mortality in malignant pleural mesothelioma (MPM), and (2) whether first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT impacts on local recurrence or survival.Methods: From July 1993 to June 1996, 63 patients with localized MPM were randomized to either PDT or no PDT. The tumors of 15 patients could not be debulked to 5 mm. Patients assigned to PDT (n=25) and no PDT (n=23) were similar with respect to age, sex, tumor volume, and histology.Results: The type of resection (11 pleurectomies and 14 pneumonectomies vs. 12 pleurectomies and 11 pneumonectomies), length postoperative stay, and ICU time were comparable (PDT vs. no PDT). There was one operative death (hemorrhage), and each group had two bronchopleural fistulas. Postoperative staging divided patients into the following categories: stage I: PDT, 2, no PDT, 2; stage II: PDT, 2, no PDT, 2; stage III, PDT, 21; no PDT, 17; stage IV, PDT, 0; 0; no PDT, 2. Comparable numbers of CIT cycles were delivered. Median survival for the 15 non-debulked patients was 7.2 months, compared to 14 months for the 48 patients on protocol. There were no differences in median survival (14.4 vs. 14.1 months) or median progression-free time (8.5 vs. 7.7 months), and sites of first recurrence were similar.Conclusions: Aggressive multimodal therapy can be delivered for patients with higher stage MPM. First-generation PDT does not prolong survival or increase local control for MPM.
29 schema:genre article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf N4a2036c496ad493ca0b11feacf9bf223
33 Nf8baa904ad1f48d6902f265ed164777c
34 sg:journal.1105545
35 schema:keywords CIT cycles
36 First-generation PDT
37 ICU time
38 III trial
39 age
40 aggressive multimodal therapy
41 approach
42 bronchopleural fistula
43 categories
44 cisplatin
45 comparable number
46 control
47 cycle
48 death
49 differences
50 disease
51 first recurrence
52 first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT
53 fistula
54 group
55 higher stage MPM
56 histology
57 immunochemotherapy
58 interferon α-2b
59 intraoperative photodynamic therapy
60 intrapleural photodynamic therapy
61 length postoperative stay
62 local control
63 local disease
64 local recurrence
65 malignant pleural mesothelioma
66 median progression-free time
67 median survival
68 mesothelioma
69 minimum morbidity
70 months
71 morbidity
72 mortality
73 multimodal approach
74 multimodal therapy
75 non-debulked patients
76 number
77 operative deaths
78 patients
79 phase III
80 phase III trials
81 photodynamic therapy
82 pleural mesothelioma
83 postoperative cisplatin
84 postoperative immunochemotherapy
85 postoperative stay
86 progression-free time
87 progressive local disease
88 protocol
89 recurrence
90 report
91 resection
92 respect
93 results
94 sex
95 sites
96 stage I
97 stage II
98 stage III
99 stage IV
100 stage MPM
101 stay
102 surgery
103 survival
104 tamoxifen (CIT) immunochemotherapy
105 therapy
106 time
107 trial of surgery
108 trials
109 tumor volume
110 tumors
111 type of resection
112 types
113 volume
114 α-2b
115 schema:name Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
116 schema:pagination 628-633
117 schema:productId N005ecf486c574ff1a54830f387080a22
118 N29db01e336654b1a94d2b4ea9aa1cf6b
119 Ndbaa6ffb87bf456ca890e2f2e8451f30
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051247127
121 https://doi.org/10.1007/bf02303746
122 schema:sdDatePublished 2021-12-01T19:11
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher Na75250503d924fca97fac453c5fb909c
125 schema:url https://doi.org/10.1007/bf02303746
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N0052c448467643ad9f04f778ba52e85b rdf:first sg:person.01306041342.14
130 rdf:rest Ndd02124a6497483d93dc471115f5465c
131 N005ecf486c574ff1a54830f387080a22 schema:name dimensions_id
132 schema:value pub.1051247127
133 rdf:type schema:PropertyValue
134 N181229cce84047c790eb242acf9b5173 rdf:first sg:person.0763326335.92
135 rdf:rest N0052c448467643ad9f04f778ba52e85b
136 N26116fda0d9b4509965b27291a0ccbe9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Intraoperative Care
138 rdf:type schema:DefinedTerm
139 N2696d5ce22b0492db26009df008e8e21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Prospective Studies
141 rdf:type schema:DefinedTerm
142 N29db01e336654b1a94d2b4ea9aa1cf6b schema:name doi
143 schema:value 10.1007/bf02303746
144 rdf:type schema:PropertyValue
145 N2f0470cc0bea4039b3a5efd7218b6b11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Survival Analysis
147 rdf:type schema:DefinedTerm
148 N385ba795747f473a8c07718a52620f24 rdf:first Ne79e3a9dee284535adbcb07869c62ccc
149 rdf:rest Ne0bbde2514824cd4adf2584a36d9be27
150 N3e1c41672f8241aa85b2f7c1e00bbad3 rdf:first sg:person.014154611317.32
151 rdf:rest N51aeda3899eb4fdf868362f53e3e443a
152 N40672a08826742b2a35657ccbb647f37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Humans
154 rdf:type schema:DefinedTerm
155 N484c3567b13741949daac0a390baeeb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Aged
157 rdf:type schema:DefinedTerm
158 N4a2036c496ad493ca0b11feacf9bf223 schema:issueNumber 8
159 rdf:type schema:PublicationIssue
160 N51aeda3899eb4fdf868362f53e3e443a rdf:first sg:person.015660165207.76
161 rdf:rest Na4920375241b417ca7e4ce7792822419
162 N543bef448f2242119a96e2827ddb597a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Photochemotherapy
164 rdf:type schema:DefinedTerm
165 N73408d7625604366a62eb357d4adb7a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Pleural Neoplasms
167 rdf:type schema:DefinedTerm
168 N878101eae1f04370a32a2a61003a0888 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Middle Aged
170 rdf:type schema:DefinedTerm
171 Na4920375241b417ca7e4ce7792822419 rdf:first sg:person.014210640617.24
172 rdf:rest rdf:nil
173 Na75250503d924fca97fac453c5fb909c schema:name Springer Nature - SN SciGraph project
174 rdf:type schema:Organization
175 Na77a5e48358f4139a690392bedf04995 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Interferon-alpha
177 rdf:type schema:DefinedTerm
178 Nb0ad0a07ac2e4d43b6ad4e8850da10c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Recombinant Proteins
180 rdf:type schema:DefinedTerm
181 Nb304d83e58884f60a548b108cc2af0f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Combined Modality Therapy
183 rdf:type schema:DefinedTerm
184 Nb96a1976289c4d1599bf495193190628 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Female
186 rdf:type schema:DefinedTerm
187 Nc4592f11f33b4ffab3b6386b72518a64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Tamoxifen
189 rdf:type schema:DefinedTerm
190 Ncebbee43f1554ae7bbbc44e57d0a6951 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Interferon alpha-2
192 rdf:type schema:DefinedTerm
193 Ncf2c57ca990b493f95c76ace98bfbf95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Cisplatin
195 rdf:type schema:DefinedTerm
196 Nd1dac1e8a4494e62a964895f684aab63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Antineoplastic Combined Chemotherapy Protocols
198 rdf:type schema:DefinedTerm
199 Nd60d8f64436f461a8688ec58a264e1c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Mesothelioma
201 rdf:type schema:DefinedTerm
202 Ndbaa6ffb87bf456ca890e2f2e8451f30 schema:name pubmed_id
203 schema:value 9416409
204 rdf:type schema:PropertyValue
205 Ndd02124a6497483d93dc471115f5465c rdf:first sg:person.01032321717.09
206 rdf:rest N385ba795747f473a8c07718a52620f24
207 Ne0bbde2514824cd4adf2584a36d9be27 rdf:first sg:person.01046205245.21
208 rdf:rest N3e1c41672f8241aa85b2f7c1e00bbad3
209 Ne0bd834aff2a436db683f70664bfa866 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Adult
211 rdf:type schema:DefinedTerm
212 Ne79e3a9dee284535adbcb07869c62ccc schema:affiliation grid-institutes:grid.94365.3d
213 schema:familyName Thomas
214 schema:givenName Gunther
215 rdf:type schema:Person
216 Nf8baa904ad1f48d6902f265ed164777c schema:volumeNumber 4
217 rdf:type schema:PublicationVolume
218 Nfd2133ce507d4a30bf92717dbde9b467 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Male
220 rdf:type schema:DefinedTerm
221 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
222 schema:name Medical and Health Sciences
223 rdf:type schema:DefinedTerm
224 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
225 schema:name Oncology and Carcinogenesis
226 rdf:type schema:DefinedTerm
227 sg:journal.1105545 schema:issn 1068-9265
228 1534-4681
229 schema:name Annals of Surgical Oncology
230 schema:publisher Springer Nature
231 rdf:type schema:Periodical
232 sg:person.01032321717.09 schema:affiliation grid-institutes:grid.94365.3d
233 schema:familyName Kranda
234 schema:givenName Karen
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032321717.09
236 rdf:type schema:Person
237 sg:person.01046205245.21 schema:affiliation grid-institutes:grid.94365.3d
238 schema:familyName Russo
239 schema:givenName Angelo
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046205245.21
241 rdf:type schema:Person
242 sg:person.01306041342.14 schema:affiliation grid-institutes:grid.94365.3d
243 schema:familyName Temeck
244 schema:givenName Barbara K.
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306041342.14
246 rdf:type schema:Person
247 sg:person.014154611317.32 schema:affiliation grid-institutes:grid.48336.3a
248 schema:familyName Smith
249 schema:givenName Paul
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014154611317.32
251 rdf:type schema:Person
252 sg:person.014210640617.24 schema:affiliation grid-institutes:grid.94365.3d
253 schema:familyName Steinberg
254 schema:givenName Seth M.
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014210640617.24
256 rdf:type schema:Person
257 sg:person.015660165207.76 schema:affiliation grid-institutes:grid.48336.3a
258 schema:familyName Friauf
259 schema:givenName Walt
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015660165207.76
261 rdf:type schema:Person
262 sg:person.0763326335.92 schema:affiliation grid-institutes:grid.94365.3d
263 schema:familyName Pass
264 schema:givenName Harvey I.
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763326335.92
266 rdf:type schema:Person
267 sg:pub.10.1007/bf02303538 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003120273
268 https://doi.org/10.1007/bf02303538
269 rdf:type schema:CreativeWork
270 sg:pub.10.1007/bf02307026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018395434
271 https://doi.org/10.1007/bf02307026
272 rdf:type schema:CreativeWork
273 sg:pub.10.1038/bjc.1991.474 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014661732
274 https://doi.org/10.1038/bjc.1991.474
275 rdf:type schema:CreativeWork
276 grid-institutes:grid.48336.3a schema:alternateName National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA
277 schema:name National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA
278 rdf:type schema:Organization
279 grid-institutes:grid.94365.3d schema:alternateName Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA
280 From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA
281 Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA
282 schema:name Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA
283 From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA
284 Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA
285 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...